Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Leases (2019 - 2025)

Guided Therapeutics' Current Leases history spans 7 years, with the latest figure at $76000.0 for Q3 2025.

  • For Q3 2025, Current Leases fell 25.49% year-over-year to $76000.0; the TTM value through Sep 2025 reached $76000.0, down 25.49%, while the annual FY2024 figure was $106000.0, 16.48% up from the prior year.
  • Current Leases for Q3 2025 was $76000.0 at Guided Therapeutics, down from $104000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $110000.0 in Q1 2025 and bottomed at $42000.0 in Q1 2021.
  • The 5-year median for Current Leases is $82000.0 (2023), against an average of $82684.2.
  • The largest annual shift saw Current Leases tumbled 57.58% in 2021 before it soared 66.67% in 2022.
  • A 5-year view of Current Leases shows it stood at $67000.0 in 2021, then rose by 17.91% to $79000.0 in 2022, then increased by 15.19% to $91000.0 in 2023, then rose by 16.48% to $106000.0 in 2024, then dropped by 28.3% to $76000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Current Leases are $76000.0 (Q3 2025), $104000.0 (Q2 2025), and $110000.0 (Q1 2025).